

INTERNATIONAL
WORKSHOP ON
**HIV &
WOMEN**
2022



FROM ADOLESCENCE
TO MENOPAUSE

VIRTUAL MEETING
6-8 APRIL 2022



Program



We are thrilled to welcome you to the 12th International Workshop on HIV and Women. We are very disappointed that we are unable to meet together again this year, but we still hope that we can all enjoy the meeting and feel the virtual hug we are all sharing.

Our workshop focuses on a global perspective on treatment and management of women living with HIV: developing a better understanding of different barriers and issues around the globe, and helping identify ways forward for improving health of women. Despite women representing more than 50% of the world's population living with HIV, before we created this workshop there were few opportunities to debate and discuss research issues specific to HIV and women.

It is incredible how much we have grown over the past 12 years. This workshop provides a unique platform for experts involved in research and treatment of women living with HIV to present and discuss the latest developments in the field and identification of treatment strategies for the future.

It is an outstanding opportunity for health care providers, researchers, government, industry and community to discuss, debate, and further their knowledge on the issues related to HIV and women. The meeting also provides a forum for new investigators to present and receive feedback on their work, and to present to experts they view as mentors and inspiration for their work.

Our meeting emphasizes and encourages attendees to learn from each other and experts in the field of HIV and related health, and then to dialogue on the issues, the gaps and the opportunities for further learning and research. Many of the attendees come each year and have formed valuable relationships and partnerships which have led to collaborative projects. The debates and roundtables are an important vehicle to discuss the issues and challenge dogma. Our poster discussions allow further interaction and contributions to each other's work.

Given the ongoing COVID pandemic we felt it important to have an update on the biomedical advances and their impact on women. We also have included a presentation on how the pandemic has impacted HIV service delivery. Lastly we have a terrific panel who will discuss how the COVID-19 pandemic has impacted women clinicians and researchers and the work that they do.

Our debate this year is on the controversial issue of the relationship on the use of integrase inhibitors on weight gain which has been observed primarily in women of color. We look forward to how our debaters address this issue.

Given our workshop is largely attended by women, we thought an important topic to discuss this year is women and their role in leadership. Although the "gender gap" is improving in academia and beyond, there is still work to do.

Our final section is going to address "hot topics" that are important to women including breast feeding, safety of drugs in pregnancy, PrEP, aging and the immune system, and mental health and loneliness.

We look forward to "seeing you virtually " soon.

On behalf of the Organizing Committee,

Sharon Walmsley
Workshop Chair



**Sharon Walmsley,
C.M. MD, FRCPC**

University Health
Network, Canada





Abstracts

Accepted abstracts are published in **Reviews in Antiviral Therapy & Infectious Diseases, Volume 2022_1**.

Certificate of Attendance

Your certificate of attendance with your CME credits will be sent to you upon completion of the post-meeting survey.

Feedback

Your feedback is very valuable to us and enables us to further improve this workshop. After each session a short questionnaire will pop-up and we would like to ask you to take a minute to complete it. After the workshop, a survey will be sent to you via email, with other questions to improve this workshop.

Group picture

We ask you all to take a photo of yourself watching the workshop and send it to the workshop secretariat at lara@amededu.com or christina.moustakaki@amededu.com. We will collate the images and send out the finished virtual group photo at the end of the workshop.

Networking

The Meeting Hub allows you to connect and communicate with other attendees. Once you have located an attendee you want to connect with, click the Connect button. Once the other attendee accepts your request, you can choose to interact by starting a live chat or live video call. You can also schedule a meeting at a later time, send messages and take notes. Contact information for all attendees you have connected with will be included when you export contacts.

Notes

You will be able to take notes during the virtual workshop. Any notes that you take throughout the event can be exported by selecting the Export icon in the top right of the screen near your profile image.

Virtual Workshop Portal

OnAIR is the virtual meeting platform being used for HIV & Women 2022. A video tutorial on how to use the Workshop Portal can be found [here](#).

To log in, please follow this link and use the login credentials you have received per email. OnAir Virtual Portal works best with Google Chrome. It may not be compatible with your mobile phone or tablet. To access the sessions, we advise you to use your computer.

Social Media

We encourage you to post news about **#HIVWOMEN** to your social media accounts and tweet about **#HIVWOMEN** as often as you like during the workshop. You can either post your own tweet to your followers using the hashtag **#HIVWOMEN** or retweet a message through the official [@Academic_MedEdu](#) account.

Posters and Guided Poster Tours

During the virtual workshop all accepted posters are displayed in the Poster Gallery. The Poster Gallery is always open for you. The Guided Poster Tours will be held as parallel sessions on Wednesday, 6 April, at the conclusion of the plenary program. The Poster Viewing Session will take place on Thursday, 7 April, at 1:50 PM EDT, you can visit the posters and interact with the presenters - just like if it was a face-to-face workshop.

Presentations and Webcasts

ame Videos, abstracts, and other materials will be made available on www.AcademicMedicalEducation.com 3 weeks after the meeting. You will be able to watch the presentations on the workshop virtual portal until this time.

Time Zones

Times are in Eastern Daylight Time. If you need to convert the times to your timezone, this website might be of interest to you:

<https://www.worldtimebuddy.com/>

Our Team



Lara da Silva Miguel
Project Manager
Lara@amededu.com



Christina Moustakaki
Jr. Project Coordinator
Christina.Moustakaki@amededu.com

Disclaimer: This workshop aims to offer participants the opportunity to share information. Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.



The International Workshop on HIV & Women 2022 Utrecht (Livestream), Netherlands, 06/04/2022-08/04/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **7 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.





Organizing Committee



**Annette Haberl
MD**
HIVCENTER University Hospital Frankfurt,
Germany



**Catherine Hankins
MD, PhD, FRCPC, CM**
McGill University,
Canada



**Margaret Johnson
MD, FRCP**
Royal Free London NHS Foundation Trust,
United Kingdom



**Fungai Murau
MCIM, MA**
Independent Consultant (HIV),
United Kingdom



**Angelina Namiba
BA Hons**
4MNetwork of Mentor Mothers,
United Kingdom



**Natella Rakhmanina
MD, PhD, FAAP, FCP, AAHIVS**
Children's National Hospital,
United States



**Sharon Walmsley
C.M. MD, FRCPC**
University Health Network,
Canada

Scientific Committee

Karoline Aebi-Popp, MD, MSc
University Hospital Bern, Switzerland

Sergii Antoniak, MD
Gromashevsky Institute of
Epidemiology and Infectious
Diseases, National Academy of
Medical Sciences of Ukraine, Ukraine

Dawn Averitt
The Well Project/WRI, United States

Olga Belyaeva
Eurasian Network of People who
Use Drugs (ENPUD), Ukraine

Marina Bobkova, MD, PhD
Gamaleya Center for Epidemiology
and Microbiology, Russian Ministry
of Health, Russia

Claudia Cortes, MD
Universidad de Chile, Chile

Dázon Dixon Diallo, MPH
Sister Love, United States

Shirin Heidari, PhD
Graduate Institute of International
and Development Studies,
Switzerland

Mirjam-Colette Kempf, MD, MPH
University of Alabama at
Birmingham, United States

Justyna Kowalska, MD, PhD
Hospital for Infectious Diseases,
Poland

Allen Kyendikuwa, BA
Uganda Youth Coalition on
Adolescent SRHR and HIV (CYSRA),
Uganda

Mona Loutfy, MD, FRCPC, MPH
Women's College Research
Institute (Univ. Toronto), Canada

Mariana Mardarescu, MD, PhD
National Institute for Infectious
Diseases "Prof. Dr. Matei Bals",
Romania

Catia Marzolini, PharmD, PhD
University Hospital Basel,
Switzerland

Deborah Money, MD, FRCSC
University of British Columbia,
Canada

Teresia Otieno
Athena Network, United States

Lena Serghides, PhD
University Health Network, Canada

**William R. Short, MD, MPH,
FIDSA**
University of Pennsylvania,
United States

Shema Tariq, PhD, FRCP
University College London,
United Kingdom

Patricia Vasquez, MD
Hospital San Juan de Dios, Chile

Marta Vasylyev, MD
Astar Medical Center, Ukraine

Markella Zanni, MD
MGH/Harvard Medical School,



Day 1 - Wednesday, 6 April 2022







EDT	CEST		
11:00 AM	5:00 PM	Opening of the Workshop Sharon Walmsley, C.M. MD, FRCPC University Health Network, Canada	
Session 1: COVID & HIV & Women - Update on the Biomedical Advances Chairs: Sharon Walmsley, C.M. MD, FRCPC - University Health Network, Canada William R. Short, MD, MPH, FIDSA - University of Pennsylvania, United States			
11:05 AM	5:05 PM	 COVID-19 Vaccines – Where Do We Stand? Where Are We Headed? Marylyn Addo, MD, PhD - University Medical Center Hamburg-Eppendorf, Germany	
11:25 AM	5:25 PM	The Representative Studies Rubric: 12 Steps to Enhance the Representation of Women and Minorities in HIV Research Brian Minalga, Fred Hutchinson Cancer Research Center, United States	#1
11:35 AM	5:35 PM	An Analysis of Utilization of Post Gender-Based Violence Care Among Women Between Pre and COVID-19 Timeframes Across Select African Countries Cosima Lenz, Elizabeth Glaser Pediatric AIDS Foundation, United States	#2
11:45 AM	5:45 PM	Modeling HIV Infections Averted by Treating Urban, Adult Zambian Women at High-Risk for HIV for Female Genital Schistosomiasis Kristin Wall, Emory University, United States	#3
11:55 AM	5:55 PM	A Comparison of the Factors Associated with Depression Among Older Black Women and Men Living With HIV Frank Spinelli, ViiV Healthcare, United States	#5
12:05 PM	6:05 PM	Live Q&A - Discussion with the Audience	
12:35 PM	6:35 PM	Virtual Break - Time to Network	
Session 2: Impact of COVID-19 on HIV Service Delivery Chairs: Fungai Murau, MCIM, MA - Independent Consultant (HIV), United Kingdom Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS - Children's National Hospital, United States			
12:50 PM	6:50 PM	 HIV Service During the COVID-19 Pandemic: Disruption, Telemedicine, and Equity Laura Waters, MD, FRCP - Central & North West London NHS Foundation Trust, United Kingdom	
1:10 PM	7:10 PM	Live Q&A - Discussion with the Audience	
1:20 PM	7:20 PM	Panel Discussion: Impact of COVID-19 on Women Clinicians & Researchers	
		 Charu Kaushic, PhD - McMaster University, Canada  Sahera Dirajlal-Fargo, MD - Case Western Reserve University, United States  Judith Kose, MD, PhD - Elizabeth Glaser Pediatric AIDS Foundation, Kenya  Longret Kwardem - 4M Mentor Mothers Network CIC, United Kingdom	
2:00 PM	8:00 PM	Virtual Break - Time to Network	



2:15 PM	8:15 PM	Guided Poster Tours (3 Parallel Sessions)	
		Guided Poster Tour 1: Antiretroviral Therapy, HPV Vaccines & Women's Health Moderator: Mariana Mardarescu, Mirjam-Colette Kempf	
		Bone Health in Aging Women (BEING) Study: Impact of Switching Antiretroviral Agents on Bone Mineral Density Sharon Walmsley, University Health Network, Canada	#15
		HIV Treatment in Pregnancy Over Time: Gaps Between Guidelines and Clinical Practice Constantin von Schoeppenthau, University Hospital Frankfurt, HIVCENTER, Germany	#16
		Age-Specific Human Papillomavirus Vaccine Coverage Among Women Living With HIV in Ontario, Canada Catharine Chambers, University of Toronto, Canada	#17
		Use of Antiretroviral Therapy in Pregnancy and Association with Birth Outcome Among Women With HIV in Denmark: A Nationwide, Population-Based Cohort Study Ellen Moseholm, Copenhagen University Hospital, Denmark	#18
		Q & A	
		Guided Poster Tour 2: Mental Health & Substance Use in HIV Women Moderator: Lena Serghides, Shema Tariq	
		Prevalence, Correlates, and Outcomes of Major or Persistent Pain Among Women Living With HIV in Metro Vancouver, Canada Sophia Ly, Centre for Gender & Sexual Health Equity, Canada	#19
		Substance Use Treatment Utilization Among Women With and at Risk for HIV in the Southern United States Aditi Ramakrishnan, Emory University, United States	#20
		Adolescent Mothers Affected by HIV in South Africa: An Exploration of Risk and Protective Factors for Maternal Mental Health Kathryn Roberts, University College of London, United Kingdom	#21
		Mental and Sexual Health in Women Living With HIV Aged 40-60 in Denmark: A Cross-Sectional Study Ditte Scofield, Copenhagen University Hospital, Denmark	#22
		Q & A	
		Guided Poster Tour 3: Issues Related to Pregnancy & Breastfeeding Moderator: Claudia Cortes, Deborah Money	
		Missed Opportunities to Support Pregnant Women Living With HIV in Zambia: Why Are So Many Women Ineligible for a Couples-Based Intervention? Karen Hampanda, University of Colorado School of Medicine, United States	#23
		Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living With HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials Parul Patel, ViiV Healthcare, United States	#24
		Reproductive Feto-Toxicity Studies to Evaluate Dolutegravir in Combination With Emtricitabine and Tenofovir in Pregnant Mice on a Folate Deficient Diet Haneesha Mohan, University Health Network, Canada	#25
		Infant Feeding Options for People Living With HIV - 'The Optimal Scenario & Context of Care': Guidance for Healthcare Providers and PLHIV Kirsten Machon, Positive Women Victoria, Australia	#26
		Q & A	
2:55 PM	8:55 PM	End of Day 1	



DAY 2 - Thursday, 7 April 2022

EDT	CEST	
10:00 AM	4:00 PM	Industry-Supported Satellite Symposium
10:45 AM	4:45 PM	Virtual Break - Time to Network
Session 3: Debate - Integrase Inhibitors Cause Weight Gain		
Moderator: Catherine Hankins, MD, PhD, FRCPC, CM - McGill University, Canada		
11:00 AM	5:00 PM	 Opening Words Catherine Hankins, MD, PhD, FRCPC, CM - McGill University, Canada
11:04 AM	5:04 PM	 Healthcare Provider: For the Proposition Chloe Orkin, MBChB, FRCP, MD - Queen Mary University of London, United Kingdom
11:11 AM	5:11 PM	 Healthcare Provider: Against the Proposition Daniel Kuritzkes, MD - Brigham and Women's Hospital; Harvard Medical School, United States
11:18 AM	5:18 PM	 Community Representative: For the Proposition Doreen Moraa Moracha - I Am a Beautiful Story, Kenya
11:22 AM	5:22 PM	 Community Representative: Against the Proposition Angelina Namiba, BA Hons - 4MNetwork of Mentor Mothers, United Kingdom
11:26 AM	5:26 PM	Discussion with the Audience
11:51 AM	5:51 PM	Rebuttal
11:55 AM	5:55 PM	Voting
12:00 PM	6:00 PM	Virtual Break - Time to Network
Session 4: Abstract - Driven Presentations: Pregnancy & Breastfeeding		
Chairs: Margaret Johnson, MD, FRCP - Royal Free London NHS Foundation Trust, United Kingdom Patricia Vasquez, MD - Hospital San Juan de Dios, Chile		
12:15 PM	6:15 PM	Pregnancy Characteristics and Outcomes of Women With Vertically-Acquired HIV in the UK, 2006-2021 Helen Peters, UCL Great Ormond Street Institute of Child Health, United Kingdom #6
12:25 PM	6:25 PM	Understanding the Factors That Influence Infant-Feeding Decisions Among Women Living With HIV in the UK Bakita Kasadha, University of Oxford, United Kingdom #7
12:35 PM	6:35 PM	"It Was the Best Decision!" - Experiences of Breastfeeding Mothers Living With HIV in Germany (SISTER Study) Lila Haberl, Goethe University Frankfurt, Heinrich Heine University Düsseldorf, Germany #8
12:45 PM	6:45 PM	Using a Universal PrEP Provision Approach in Pre- and Postnatal Care Services Increases Uptake of PrEP Among Pregnant and Breastfeeding Women (PBFW) in Eswatini Maria Nnambalirwa, Elizabeth Glaser Pediatric AIDS Foundation, Eswatini #9
12:55 PM	6:55 PM	Live Q&A - Discussion with the Audience
Session 5: Women Leadership		
Chairs: Margaret Johnson, MD, FRCP - Royal Free London NHS Foundation Trust, United Kingdom Angelina Namiba, BA Hons - 4MNetwork of Mentor Mothers, United Kingdom		
1:15 PM	7:15 PM	 Women in Medicine & the Gender Pay Gap Dame Jane Dacre, DBE, MD, FRCP - UCL Medical School, United Kingdom
1:40 PM	7:40 PM	Live Q&A - Discussion with the Audience
1:50 PM	7:50 PM	Poster Viewing Session
2:20 PM	8:20 PM	End of Day 2



DAY 3 - Friday, 8 April 2022

EDT	CEST		
11:00 AM	5:00 PM	Introduction to Day 3 Annette Haberl, MD HIVCENTER University Hospital Frankfurt, Germany	
Session 6: Abstract - Driven Presentations: Comorbidity in Women Living with HIV Chairs: Annette Haberl, MD - HIVCENTER University Hospital Frankfurt, Germany Teresia Otieno - ATHENA Network, United States			
11:05 AM	5:05 PM	Subclinical Atherosclerosis and Immune Activation Among US Females vs. Males with HIV Markella Zanni, Massachusetts General Hospital / Harvard Medical School, United States	#10
11:15 AM	5:15 PM	Reduced Cardiac Strain Among Women With HIV Relates to Inflammatory Monocyte Activation Mabel Toribio, Massachusetts General Hospital, United States	#11
11:25 AM	5:25 PM	Increasing Prevalence of Gestational Diabetes in Women Living With HIV in the UK and Ireland Laurette Bukasa, University College London Great Ormond Street Institute of Child Health, United Kingdom	#12
11:35 AM	5:35 PM	Age at Menopause in Women Living With and Without HIV in the Children and Women: AntiRetrovirals and Markers of Aging (CARMA) and the British Columbia CARMA-CHIWOS Collaboration (BCC3) Studies Shayda Swann, The University of British Columbia Faculty of Medicine / BC Women's Hospital and Health Centre Women's Health Research Institute, Canada	#13
11:45 AM	5:45 PM	Understanding the Effects of Repeat-Motherhood Among Young Women Living With HIV and Their Children: Evidence From a South African Sample Katharina Haag, University College London, United Kingdom	#14
11:55 AM	5:55 PM	Live Q&A - Discussion with the Audience	
12:10 PM	6:10 PM	Virtual Break - Time to Network	
Session 7: Hot Topics in HIV & Women Chairs: Natella Rakhmanina, MD, PhD, FAAP, FCP, AAHIVS - Children's National Hospital, United States Fungai Murau, MCIM, MA - Independent Consultant (HIV), United Kingdom			
12:25 PM	6:25 PM	 Breastfeeding & HIV Yvonne Gilleece, MB, BCh, BAO - Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust, United Kingdom	
12:40 PM	6:40 PM	 HIV Pre-exposure Prophylaxis for Cisgender Women: Clinical Trials & Implementation Challenges Rachel Scott, MD, MPH - Medstar Washington Hospital Center, United States	
12:55 PM	6:55 PM	 New ART During Pregnancy Alice Tseng, B.Sc.Ph., PharmD, FCSHP, AAHIVP - University of Toronto, Canada	
1:10 PM	7:10 PM	 Aging & Immune System: Women-Specific Aspects Peter W. Hunt, MD - University of California San Francisco, United States	
1:25 PM	7:25 PM	 Mental Health & Loneliness Maile Young Karris, MD - University of California San Diego, United States	
1:40 PM	7:40 PM	Live Q&A - Discussion with the Audience	
Concluding Remarks & Closure of the Workshop			
2:10 PM	8:10 PM	Sharon Walmsley, C.M. MD, FRCPC University Health Network, Canada	
2:15 PM	8:15 PM	End of Day 3	



7 April 2022

4 Women: 4 Seasons of Stigma



EDT	CEST	
10:00 AM	4:00 PM	<p>Welcome Chair: Ama Appiah, BSc, MRPharmS - ViiV Healthcare, United Kingdom</p>
10:02 AM	4:02 PM	<p>Experiences of Stigma</p> <p> Lilly-Millie Child Living with HIV Youth Committee, United Kingdom</p> <p> Rena Janamnuaysook, MBA Institute of HIV Research and Innovation, Thailand</p> <p> Thais Renovatto, MBA Associated British Foods and Author, Brazil</p> <p> Fungai Murau, MCIM, MA Independent Consultant (HIV), United Kingdom</p>
10:22 AM	4:22 PM	<p> HIV-Related Stigma and Its Health Implications Dagny Clea Krankowska, MD Department of Infectious and Tropical Diseases and Hepatology, Medical University of Warsaw, Hospital for Infectious Diseases, Poland</p>
10:32 AM	4:32 PM	<p>Live Q&A - Discussion with the Speakers</p>
10:45 AM	4:45 PM	<p>End of Symposium</p>



Faculty



INVITED SPEAKER

**Marylyn Addo,
MD, PhD**

University Medical Center
Hamburg-Eppendorf, Germany

Marylyn Addo studied Medicine at the University of Bonn with study years abroad in Strasbourg, France and Lausanne, Switzerland (Erasmus exchange program). After completing a Master's Degree in "Applied Molecular Biology of Infectious Diseases" (MSc AMBID, on a DAAD scholarship) and the Diploma in Tropical Medicine and Hygiene (DTM & H) at the London School for Hygiene and Tropical Medicine, she pursued postdoctoral research years with focus on HIV Immunology at the Massachusetts General Hospital (MGH)/Harvard Medical School (HMS) in Boston, USA, funded through the DFG Emmy Noether program. After completing her specialist training at MGH and Brigham's and Women's Hospital in internal medicine (2007) and infectious diseases (2010), she worked as staff attending physician in infectious diseases at the MGH until 2013. From 2010-2013 she also worked as a PI and research group leader at the Ragon Institute of MGH, MIT and Harvard and as an Assistant Professor in Medicine at Harvard Medical School. Since her appointment as first Professor of the German Center for Infection Research (DZIF) (W2 Emerging Infections) in 2013, Professor Addo has headed a translational research program on virus immunology and vaccine development for "Emerging Infections" at the University Medical Center Hamburg-Eppendorf (UKE). In 2017 she was appointed to the W3 professorship of Infectious Diseases at the UKE and is currently Head of the Infectious Diseases Division at the UKE Department of Internal Medicine. Since January 2022 she serves as the Founding Director of the new Institute for Infection Research and Vaccine Development (IIRVD) at the UKE. Her research group focuses on immunity to infectious diseases and early vaccine development of vaccines against emerging or re-emerging pathogens such as Ebola, MERS and now SARS-CoV-2. She lives in Hamburg, Germany and has two children.

Potential conflict of interest:
Gilead



INVITED SPEAKER

**Dame Jane Dacre,
DBE, MD, FRCP**

UCL Medical School,
United Kingdom

Jane is the former Director of UCL Medical School and an honorary consultant rheumatologist, at Whittington Health in London. She is Professor of Medical Education at UCL and the President of the Medical Protection Society and a specialist advisor to parliament on the Health and Care Committee. She is the immediate past president of the Royal College of Physicians and was also vice chair of the Academy of Medical Royal Colleges, medical director of MRCPUK examination, academic vice president of the RCP and a GMC council member. Her research is in medical education focusing on assessment and equality.

She was the lead for the Department of Health and Social Care review of the Gender Pay Gap in Medicine, with Professor Carol Woodhams from Surrey University Business School. This review 'Mend the Gap: The Independent Review into Gender Pay Gaps in Medicine in England' was published in December 2020. She now chairs the gender pay gap implementation advisory group.

Potential conflict of interest:
DHSC contract to chair Gender Pay Gap implementation group and Chair HSCC Expert Panel



INVITED SPEAKER

**Sahera Dirajlal-Fargo,
MD**

Case Western Reserve
University, United States

Sahera Dirajlal-Fargo is a pediatric infectious disease physician at Case Western Reserve University School of Medicine and Rainbow Babies and Children's Hospital. She worked with the Baylor Pediatric AIDS Initiative throughout Africa and has obtained her pediatric infectious disease training at Children's National Medical Center in Washington, DC. Her research focuses on cardiometabolic complications of HIV in children and youth in the US and sub-Saharan Africa and is supported by the National Institutes of Health and PHACS (The Pediatric HIV/AIDS Cohort Study). She has received numerous awards including loan repayment award from the National Institutes of Health, and a junior investigator award from the Pediatric Infectious Disease Society. She sits on several advisory group and board advising on global health research and training.

She is the co-director of the World Medicine Pathway at Case Western Reserve University School of medicine and associate program director of the pediatric infectious disease fellowship at Rainbow. She has continued to train students, residents and fellows both in the US and in LMICs.

No potential conflict of interest



INVITED SPEAKER

**Yvonne Gilleece,
MB, BCh, BAO**

Brighton & Sussex Medical
School and University Hospitals
Sussex NHS Foundation Trust,
United Kingdom

Yvonne Gilleece trained in Dublin and London, is Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health at Brighton & Sussex Medical School and University Hospitals Sussex NHS Trust. She is a national and international leader on HIV in Women and is Chair of the BHIVA Pregnancy Guidelines, Chair of WAVE, Chair of SWIFT, promoting research in women living with HIV. She is currently the Honorary Secretary of BHIVA. She also specialises in HIV and Bone and HIV and Hepatitis Coinfection & Liver Dysfunction.

Potential conflict of interest:
ViiV, Gilead



ORGANIZING COMMITTEE

**Annette Haberl,
MD**

HIVCENTER University Hospital
Frankfurt, Germany

Annette Haberl is a medical doctor and researcher specialized in HIV medicine. She started working in the field of HIV in 1996, implementing an interdisciplinary approach for intravenous drug users living with HIV and introducing the first once daily antiretroviral regimen. Since 1998 she runs a specialized unit for women living with HIV at the HIVCENTER of the University Hospital Frankfurt. Her research focus is on sex and gender specific issues in HIV care. AH is principal investigator of the German pregnancy registry and chair of the annual German congress on HIV and pregnancy. She is a board member of the German AIDS-society (DAIG) and co-chair of the DAIG pregnancy guidelines. She also belongs to the EACS WAVE scientific committee (Women Against Viruses in Europe).

Potential conflict of interest:

Gilead, Janssen, MSD, ViiV Healthcare



ORGANIZING COMMITTEE

**Catherine Hankins,
MD, PhD, FRCPC, CM**

McGill University, Canada

Catherine Hankins, MD, PhD, FRCPC, CM is Professor of Public and Population Health, Faculty of Medicine, McGill University; Deputy Director, Science at the Amsterdam Institute for Global Health and Development, Department of Global Health, University of Amsterdam; and Honorary Professor, London School of Hygiene and Tropical Medicine. She has authored over 250 peer-reviewed publications and reviewed for scientific journals and funding agencies in Canada, USA, Africa, and Europe. As UNAIDS's first Chief Scientific Adviser, she led the scientific knowledge translation team, developing ethical and participatory HIV prevention trial conduct guidelines and convening mathematical modelling teams to support country implementation of proven biomedical HIV prevention modalities. She was the editor of UNAIDS' popular science blog HIV This Week. Professor Hankins was Scientific Chair of the annual INTEREST conference in Africa from 2014 to 2020. She chairs the European and Developing Countries Clinical Trials Partnership's Scientific Advisory Committee and the Scientific Advisory Group of the USA National Institutes of Health HIV Prevention Trials Network. She is a trustee of the HIV Research Trust, member of the International AIDS Society Industry Liaison Forum, and board member of AVAC. She is co-Chair of Canada's COVID-19 Immunity Task Force. She was named to the Order of Canada in 2013.

Potential conflict of interest:

Merck, Gilead and ViiV



INVITED SPEAKER

Peter Hunt, MD

University of California San Francisco, United States

Peter Hunt is a Professor of Medicine in the Division of Experimental Medicine at UCSF and Co-Director of the UCSF-GIVI Center for AIDS Research for Basic and Translational Science. His primary research focus is on the inflammatory consequences of HIV infection. His translational research program seeks to understand both the mechanistic causes and clinical consequences of persistent immune activation in treated HIV infection, including its impact on age-related morbidity and mortality as well as HIV persistence. He also conducts pilot clinical trials of novel immune-based interventions designed to decrease immune activation and recently completed a term as Chair of the Inflammation Committee of the AIDS Clinical Trials Group (ACTG). Dr. Hunt has also led a translational research program in Mbarara, Uganda, focused on the predictors of immune recovery and mortality during suppressive antiretroviral therapy in that setting and has helped develop a large mucosal immunology program at San Francisco General Hospital focused on the impact of HIV on gut-associated lymphoid tissue and the determinants of microbial translocation in HIV infection. His laboratory's more recent work has focused on the impact of the inflammatory state on vaccine responsiveness and on the contribution of asymptomatic CMV infection to multiple inflammatory pathways in treated HIV infection. This latter work has led to a large clinical trial in the ACTG (A5383) and multiple linked NIH grants, which will assess whether treating asymptomatic CMV replication in treated HIV infection not only reduces systemic inflammation, but also reduces surrogate markers of cardiometabolic disease and CNS inflammation.

Potential conflict of interest:

Merck, Gilead, ViiV and Biotron



ORGANIZING COMMITTEE

Margaret Johnson, MD, FRCP

Royal Free London NHS Foundation Trust, United Kingdom

Margaret Johnson is the clinical director of the Royal Free Centre for HIV medicine and is Professor of HIV Medicine at University College London. She has been involved in the management of women with HIV infection since 1989 when she was appointed the first HIV physician in the UK. One of her first projects on appointment was the development of a designated HIV clinic for women. More recently she chaired the British HIV Association from 2004 to 2008. Together with Professor Jane Anderson she has chaired BHIVA guidelines for the management of women with HIV.

No potential conflict of interest



INVITED SPEAKER

**Maile Karris,
MD**

University of California
San Diego, United States

Maile Young Karris MD, received her MD at the John A. Burns School of Medicine at the University of Hawaii. She completed her Internal Medicine training at Oregon Health and Sciences University and her Infectious Diseases fellowship at the University of California San Diego (UCSD). She started her research career in basic science evaluating primary cell models of HIV latency. This focus evolved to the pursuit of questions evaluating the impact of antiretroviral therapy on CD4 T cell subsets and other clinical HIV outcomes. Dr. Karris also cares for people living with HIV (PLWH). Through her relationships with PLWH (many of whom are older/aging) she began to realize they were communicating personal health needs that she was not trained to manage (i.e. social isolation, loneliness, despair, severe chronic pain). This compelled her to switch her research focus to important and understudied clinical questions that impact aging with HIV. Thus, she pursued further training in aging research by becoming a Butler-Williams Scholar, a Tideswell Emerging Leader in Aging, and joining the Division of Geriatrics and Gerontology at UCSD. She also serves as a Co-Director of San Diego's Center for AIDS Research (CFAR) Clinical Investigations Core. She is a member of the AIDS Clinical Trials Group Underrepresented Populations Committee and co-chair of the HIV and Aging Working Group, as well as the CFAR Network of Integrated Clinical Systems (CNICS) and North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).

Potential conflict of interest:

Gilead Sciences, ViiV Healthcare



INVITED SPEAKER

**Charu Kaushic,
PhD**

McMaster University,
Canada

Charu Kaushic is a tenured Full Professor in the Department of Medicine in McMaster University, Hamilton, Canada. She joined as faculty in McMaster University in 2002, where she has done extensive teaching and training and built an interdisciplinary research program for last 20 years. Her research interest is women's reproductive health, specifically basic, clinical, and translational research examining susceptibility and immune responses to sexually transmitted viruses, HIV-1 and HSV-2. Charu's research has been funded by CIHR, CFI, CANFAR and OHTN and she has received numerous national and international awards. She is serving as the Scientific Director of the Canadian Institutes of Health Research (CIHR)-Institute of Infection and Immunity since 2018. In this role, she is responsible for making decisions for CIHR strategic investments in infection and immunity, nationally and internationally. She also represents CIHR and Government of Canada at various national and international forums related to infectious diseases, including COVID-19. Charu has special interest in public education, especially on women's reproductive health issues and has long term collaborations with women's community research organizations. In her current leadership role, her personal passion is to work with young women to encourage them to make careers in STEM fields and increase women in leadership roles.

No potential conflict of interest



INVITED SPEAKER

**Judith Kose,
MD, PhD**

Elizabeth Glaser Pediatric AIDS
Foundation, Kenya

Judith Kose-Otieno is the Associate Director, Pediatric and Adolescent Services for the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). She provides strategic direction at EGPAF for improving pediatric and Adolescent HIV services including TB and other comorbidities. Judith is a Pediatrician and specialist in pediatric infectious diseases with over 18 years' experience extending to public health; HIV and TB treatment; execution of clinical programs; and implementation research.

Over the years, she has supported different country programs including in the development of guidelines, national training curricula for healthcare workers and has an advisory role in several global platforms. She is currently also supporting many countries and projects on Pediatric ART Optimization efforts and is a member of the Global secretariat for the Global Accelerations for Pediatric formulations (GAP-f) to represent EGPAF. GAP-f was created as a WHO initiative to provide a sustainable mechanism dedicated to ensuring that the most needed optimal pediatric formulations are developed against the highest standards of safety and efficacy and made available to children in a timely manner.

Judith was the recipient of the 2006 International Research Health Award from The American Pediatric Association. She is a PhD candidate at Erasmus MC in Rotterdam in the Department of Viroscience. Her focus is on Pediatric and Adolescent HIV treatment outcomes.

No potential conflict of interest



INVITED SPEAKER

**Daniel Kuritzkes,
MD**

Brigham and Women's Hospital;
Harvard Medical School,
United States

Daniel Kuritzkes is the Harriet Ryan Albee Professor of Medicine at Harvard Medical School and Chief of the Division of Infectious Diseases at Brigham and Women's Hospital in Boston, Massachusetts. He received his B.S. and M.S. degrees from Yale University and his M.D. from Harvard Medical School. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection. He has chaired several multicenter studies of HIV therapy and previously chaired the AIDS Clinical Trials Group. He served as a member of the NIH Office of AIDS Research Advisory Council and as a member of the U.S. Department of Health and Human Services panel on guidelines for antiretroviral therapy. He has been a member of several editorial boards and serves as an Associate Editor of the Journal of Infectious Diseases. His research interests focus on HIV therapeutics, antiretroviral drug resistance, and HIV eradication.

Potential conflict of interest:

Atea, Gilead, Merck, Novartis, ViiV, Decoy, GlaxoSmithKline, Janssen, VitroStatics



INVITED SPEAKER

Longret Kwardem

4M Mentor Mothers Network
CIC, United Kingdom

Longret Kwardem is a Co-director of the 4M Mentor Mothers Network CIC and a Salamander Trust Associate. She is a peer researcher, public speaker and active community advocate who belongs to several networks including Making Waves, UK Community Advisory Board (UK-CAB) and Supporting Women with HIV Forum and Information (SWIFT). She is passionate about the value of peer support, peer research and the meaningful involvement of People living with HIV. She has a special interest in the sexual and reproductive health and rights (SRHR) of women and girls living with HIV and the sustainable funding of grassroots women-only spaces.

No potential conflict of interest



INVITED SPEAKER

Doreen Moraa Moracha

I Am A Beautiful Story, Kenya

Doreen Moraa Moracha recently selected as one of the Global Health Collaboration on HIV, and also a young Leader with the International AIDS Society 2021, Doreen Moraa Moracha is a young woman living with HIV from Kenya, founder of I AM A BEAUTIFUL STORY digital initiative meant to create hope and awareness and also encourage people living with HIV that there is a beautiful life even after a HIV positive diagnosis. She is a Social influencer championing against HIV/AIDs stigma using her own lived experience and has even gained a large following on social media for amplifying the HIV messaging. Doreen was awarded the Stigma Warrior award 2020 by The International Stigma Conference. She is also a member UN-WOMEN Generation Equality Youth task Force and the first cohort of the Beyond Living Life force by GNP+ and partners. In 2019 she was highlighted by WHOAFRO as one of the youth champions for the Tea on HIV Campaign.

Her highlight in the HIV response was when she was awarded the AYP community advocacy award by the National AIDS Control Council in Kenya during the Maisha conference 2021.

No potential conflict of interest



ORGANIZING COMMITTEE

Fungai Murau, MCIM, MA

Independent Consultant (HIV),
United Kingdom

Fungai Murau, MCIM, MA is a highly experienced public health expert with emphasis in the HIV and Sexual and Reproductive Health and Rights (SRHR) fields. Fungai is a passionate researcher who believes that continued research that leaves no one behind is critical to ensure that we remain on target to ending AIDS by 2030. Her expertise spans across research, contribution to policy development and conference delivery with key global platforms. Fungai currently works as an independent public health consultant focusing on policy, advocacy, and project delivery.

Previously, she has worked for Frontline AIDS, where she worked to increase understanding on quality-of-life, treatment, pregnancy, migration and the paediatric-to-adult transition for people living with and most affected by HIV. For these research areas, Fungai maintained community engagement opportunities by collaborating with community-based organisations to research, write and submit abstracts to key conferences. In 2018, Fungai led the successful delivery of Frontline AIDS at the International AIDS Conference, ensuring the meaningful representation of the vision and mission of global Linking Organizations, which are key pillars in the support of community action on HIV in developing countries. In addition to her policy and research work, she has also engaged with community-led programmes in creating sustainable sanitary products and provision initiatives.

Fungai is also a member of the Board of Trustees for three charities: SWIFT (Supporting Women with HIV Information Network), Beyond Stigma, which is dedicated to advancing the understanding and awareness of self-stigma for people living with HIV, and AMAZE, which focuses on supporting children with special educational needs and disabilities.

No potential conflict of interest



ORGANIZING COMMITTEE

Angelina Namiba, BA Hons

4MNetwork of Mentor Mothers,
United Kingdom

Angelina Namiba is originally from Kenya, she has over 24 years' experience of working in the HIV sector on different initiatives ranging from providing one-to-one support to people living with HIV, treatment advocacy, managing service delivery to facilitating, promoting and advocating for the involvement of women living with HIV in forming and informing local and national strategy and policy.

She is passionate about the Sexual Reproductive Health and Rights of women living with HIV and enabling good quality of life for young people living with HIV and has supported them around various issues and coping strategies including HIV Treatment Literacy and general well-being around living with HIV. Her special area of interest is HIV and pregnancy.

Angelina is a founder member of 4M Network, a peer mentoring project working with Mentor Mothers living with HIV. Where the MMs are trained to support their peers around the pregnancy journey and beyond. She is the lead author of the 4M Mentor Mother training manual to train other women living with HIV as Mentor Mothers.

Angelina also sits on various national and international advisory boards. These include as a patron of the National HIV Nurses Association, a lay member of the Women's Network of the Royal College of Obstetricians and Gynecologists, a member of the Organizing Committee of the annual International Women and HIV Workshop, has been a UKCAB Community representative for BHIVA, and is a Trustee of the National AIDS Trust and SAFE Kenya. She has co-authored various articles in peer-review journals and UNAIDS reports.

No potential conflict of interest



INVITED SPEAKER

**Chloe Orkin,
MBChB, FRCP, MD**

Queen Mary University of
London, United Kingdom

Chloe Orkin is Professor of HIV Medicine at Queen Mary University of London and Consultant Physician at Barts Health NHS Trust. She is the Clinical Lead for COVID-19 studies at Barts Health. Chloe is immediate past Chair of the British HIV Association, President-elect of the Medical Women's Federation and a member of the governing council for IAS. Her specialist interest is anti-retroviral therapy.

Professor Orkin has more than 200 peer-reviewed publications and has co-authored four British HIV Association guidelines on: Antiretroviral therapy, Hepatitis, Malignancy and Routine Monitoring.

Potential conflict of interest:

ViiV, Gilead, MSD, GSK, Janssen



ORGANIZING COMMITTEE

**Natella Rakhmanina,
MD, PhD, FAAP, FCP,
AAHIVS**

Children's National Hospital,
United States

Natella Rakhmanina is a Professor of Pediatrics at the George Washington University and serves as a Director of the HIV Program at Children's National Hospital in Washington, DC, USA. Dr. Rakhmanina obtained her MD degree at People's Friendship University in Moscow, Russia, and her PhD degree at the Erasmus University in Rotterdam, the Netherlands. For more than 20 years she has been providing clinical care to HIV-infected infants, children and adolescents, and continues her practice treating pediatric and adolescent patients in metropolitan DC area. She is certified in HIV medicine and is a successful clinical researcher, focusing her research on the treatment and prevention of HIV in children and adolescents and serving as a principal investigator of NIH, CDC and industry funded pediatric and adolescent HIV studies. Dr. Rakhmanina is also a Senior Technical Advisor at Elizabeth Glaser Pediatrics AIDS Foundation leading several projects on pediatric and adolescent HIV treatment in Sub-Saharan African countries. Dr. Rakhmanina is a Chair of the Committee on Pediatric AIDS at the American Academy of Pediatrics, member of the US Department of Health and Human Services Panel on the Pediatric Antiretroviral Therapy and Management Guidelines at the Office of AIDS Research Advisory Council in National Institutes of Health, member of the Pediatric Advisory Working Group at the World Health Organization, and a Regent of the Board and Chair of the Bylaws committee at the American College of Clinical Pharmacology.

No potential conflict of interest



INVITED SPEAKER

**Rachel Scott,
MD, MPH**

Medstar Washington
Hospital Center,
United States

Rachel K. Scott, MD, MPH, is the Scientific Director of Women's Health Research for MedStar Health Research Institute and the Associate Chair for Research for the Women's and Infants' Services Department of MedStar Washington Hospital Center (MWHC), where she is a practicing obstetrician/gynecologist. Dr. Scott's passion for women's health and commitment to underserved women drives both her clinical career and her commitment to clinical and translational research. She currently divides her time between clinical care and research, primarily focused on human immunodeficiency virus (HIV) and HIV prevention in women. Dr. Scott is the director of the Women's Center for Positive Living, MWHC's HIV Obstetrics and Gynecology practice within the Department of Women's and Infant Services. In addition to her clinical responsibilities, she is an assistant professor at Georgetown University Medical Center and is active in resident and medical student education and mentorship. In recognition of her expertise in maternal health and HIV, Dr. Scott was selected to be a member of the national Department of Health and Human Services Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission guidelines, which sets the preconception, antepartum, and postpartum clinical recommendations for women living with HIV and for HIV prevention/pre-exposure prophylaxis in women at risk for HIV.

Dr. Scott's current research includes a highly competitive NIH K23 award to study the behavioral health determinants of adherence during pregnancy and postpartum in women living with HIV. Additionally, she is the principal investigator on a NIH R34 award to improve HIV prevention in women at high risk for HIV and a R21 award to study placental microvasculature in pregnancies complicated by HIV.

Dr. Scott is board certified by the American Board of Obstetrics and Gynecology. She is a fellow of the American Congress of Obstetricians and Gynecologists, and she is a member of the District of Columbia Developmental Center for AIDS Research.

Potential conflict of interest:

Gilead, ViiV



INVITED SPEAKER

**Alice Tseng,
B.Sc.Pharm., PharmD,
FCSHP, AAHIVP**

University of Toronto,
Canada

Alice Tseng obtained her Bachelor of Science in Pharmacy and Doctor of Pharmacy degrees from the University of Toronto, and completed a hospital Pharmacy Residency at Toronto Western Hospital. Dr. Tseng co-founded and serves on the executive of the Ontario HIV Pharmacists Specialty Group and the Canadian HIV and Viral Hepatitis Pharmacists Network. She is a specialist consultant at the Immunodeficiency Clinic, Toronto General Hospital, and Associate Professor with the Leslie Dan Faculty of Pharmacy, University of Toronto. She has published extensively on drug interactions, adverse reactions, and HIV pharmacology and maintains an internationally recognized website/mobile app on HIV and hepatitis C drug interaction and pharmacology information (<http://app.hivclinic.ca>). Dr. Tseng is a Fellow of the Canadian Society of Hospital Pharmacists and is credentialed as an HIV Pharmacist through the American Academy of HIV Medicine.

Potential conflict of interest:

Merck, Gilead, ViiV, Abbvie



ORGANIZING COMMITTEE

Sharon Walmsley, C.M. MD, FRCPC

University Health Network,
Canada

Sharon Walmsley, MD, is the Director of Clinical Research, Immunodeficiency Clinic, Toronto Hospital, University Health Network and a Professor, University of Toronto Department of Medicine. She is a Senior Scientist at the Toronto General Hospital Research Institute and the Co- Chair of the CIHR- Canadian HIV Trials Network.

She is actively involved in the design, conduct and analysis of many clinical trials, including trials in HIV therapy; prophylaxis and treatment of opportunistic infections, and management of the complications of treatment. She has had a longstanding and strong interest in gender differences in infectious diseases and specifically in HIV in women. She has been an advocate of gender specific analysis of clinical trials of antiretroviral therapy. She is a co-investigator of the Canadian Women's HIV Study group which is currently evaluating the HPV vaccine in HIV infected women and girls, she is co-chair of the International workshop on HIV and women which is dedicated to research in HIV infected women, and a member of CHIWOS, a study of women centered care in HIV.

She holds numerous peer-reviewed publications and research awards related to clinical trials in HIV. She is the recipient of a Chair in HIV Clinical Management and Aging from the Ontario HIV Treatment Network. In June 2017, she was appointed as a Member of the Order of Canada for my contributions in HIV Research especially related to advancing therapy for women, and mentoring young female investigators.

Potential conflict of interest:

Merck, ViiV Healthcare, GSK, Gilead, Janssen



INVITED SPEAKER

Laura Waters, MD, FRCP

Central & North West London
NHS Foundation Trust,
United Kingdom

Laura Waters is a consultant physician in Sexual Health & HIV and the HIV lead at the Mortimer Market Centre, London, working predominantly in HIV outpatient services.

Laura previously worked in clinical trials at Chelsea & Westminster and Brighton, gaining an MD on ART simplification and switch and is currently principle or chief investigator on several antiretroviral trials. She is chair of the British HIV Association (BHIVA), chair of the BHIVA treatment guidelines and a previous trustee for the British Association of Sexual Health & HIV (BASHH). She is a co-author on national guidelines including the HIV testing & PEP guidelines.

She is on the HIV Clinical Reference Group, providing advice to NHS England on HIV care and co-chairs the CRG Drugs subgroup. She has published and presented widely and is a trustee for the Terrence Higgins Trust and Food Chain charities.

Potential conflict of interest:

ViiV, Gilead, Janssen, Cipla, Mylan, Merck



Support

Gold Level



Silver Level



Supporter



Endorsers



**WE ARE HERE
UNTIL THE
DAY WE
BEAT HIV**



ame

**academic
medical education**

AcademicMedicalEducation.com